ThinkstockThe American Society of Clinical Oncology’s (ASCO) annual meeting is coming to a close. Companies and cancer drug developers across the health care sector flock to this conference to share results from…
The short interest data has been released for the May 15 settlement date and for the selected pharmaceutical stocks, short interest is mixed.
Wednesday's top analyst upgrades, downgrades and initiations include Ambarella, eBay, Rite Aid, TiVo, Yahoo, Valero Energy and Virtu Financial.
With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair share of attention…
The April 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the right time to add biotech stocks.
Credit Suisse has released a report that detailed its top picks for pharmaceutical stocks for the rest of 2015.
A new report from Deutsche Bank highlights all of the known risks and focuses in on stocks that are reasonable in a pricey market.
In a new report, Cowen analysts have sights set on three major pharmaceutical stocks that they expect to have rising first-quarter earnings.
24/7 Wall St. has found four good examples of blue-chip stocks that got a little tarnished recently for one reason or another, that investors may want to reexamine.
Here are three biotech stocks that a SunTrust analyst feels could be buyout candidates, in the wake of the Pharmacyclics acquisition.
News finally broke late Wednesday that there was an official buyout of Pharmacyclics in the works by AbbVie for $21 billion.
ThinkstockAfter the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings per share (EPS) and $26.31 billion in revenue. This is compared to…
One area that makes sense for growth investors is the large cap pharmaceuticals. Here are some the top pharmaceutical stocks to buy now according to Jefferies.
Neurocrine Biosciences has announced that it will have another public offering of its common stock to raise roughly $225 million.
